Alumis
CompanyUnited States
Alumis develops one asset, in phase 3 (Envudeucitinib in psoriasis). Mostly small molecule acting on inflammation and TYK2; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 3
- 0
- Trials
- 1
- Signal
Pipeline
1Inhibits TYK2 to reduce inflammatory cytokine signaling.
Phase 3, Small molecule, Inflammation, TYK2, psoriasis
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Signals1
- Similar companies6